Aldeyra Therapeutics(ALDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALDX Aldeyra Therapeutics

Market Closed 03-27 16:00:00 EDT

1.77

-0.07

-3.80%

盘后1.77

+0.00+0.02%

19:35 EDT

High1.84	Low1.76	Vol2.61M
Open1.81	D1 Closing1.84	Amplitude4.62%
Mkt Cap106.49M	Tradable Cap85.81M	Total Shares60.16M
T/O4.66M	T/O Rate5.38%	Tradable Shares48.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALDX","market":"US","secType":"STK","nameCN":"Aldeyra Therapeutics","latestPrice":1.77,"timestamp":1774641600000,"preClose":1.84,"halted":0,"volume":2608679,"hourTrading":{"tag":"盘后","latestPrice":1.7703,"preClose":1.77,"latestTime":"19:35 EDT","volume":61097,"amount":108146.399,"timestamp":1774654513237,"change":0.0003,"changeRate":0.000169,"amplitude":0.004915},"delay":0,"changeRate":-0.038043478260869595,"floatShares":48481525,"shares":60162773,"eps":-0.563579,"marketStatus":"Market Closed","change":-0.07,"latestTime":"03-27 16:00:00 EDT","open":1.81,"high":1.84,"low":1.755,"amount":4660383.6423322,"amplitude":0.046196,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.563579,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1399003200000,"exchange":"NASDAQ","adjPreClose":1.84,"preHourTrading":{"tag":"盘前","latestPrice":1.7816,"preClose":1.84,"latestTime":"09:27 EDT","volume":15753,"amount":28116.604998900002,"timestamp":1774618063315,"change":-0.0584,"changeRate":-0.031739,"amplitude":0.021739},"postHourTrading":{"tag":"盘后","latestPrice":1.7703,"preClose":1.77,"latestTime":"19:35 EDT","volume":61097,"amount":108146.399,"timestamp":1774654513237,"change":0.0003,"changeRate":0.000169,"amplitude":0.004915},"volumeRatio":0.400467,"impliedVol":1.8557,"impliedVolPercentile":0.6892},"requestUrl":"/m/hq/s/ALDX/tweets","defaultTab":"tweets","newsList":[{"id":"2621876322","title":"Insider Makes Bold Move on Aldeyra Therapeutics Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2621876322","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621876322?lang=en_us&edition=fundamental","pubTime":"2026-03-21 10:02","pubTimestamp":1774058551,"startTime":"0","endTime":"0","summary":"New insider activity at Aldeyra Therapeutics ( ($ALDX) ) has taken place on March 20, 2026. Director Richard Douglas has significantly increased hi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/insider-makes-bold-move-on-aldeyra-therapeutics-stock-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/insider-makes-bold-move-on-aldeyra-therapeutics-stock-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2620836274","title":"Aldeyra Therapeutics Principal Financial Officer Michael Alfieri acquires USD 7,100 of common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620836274","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620836274?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:29","pubTimestamp":1773955778,"startTime":"0","endTime":"0","summary":"Michael Alfieri, Principal Financial Officer of Aldeyra Therapeutics, reported a purchase of 5,000 common shares at USD 1.42 per share.Following the transaction, Alfieri beneficially owned 7,500 common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 19, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDLKSZ8Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX","BK4162","BK4566","LU1989772923.USD","BK4534","BK4585","LU1989772840.SGD","PFG","BK4588","BK4139"],"gpt_icon":0},{"id":"2620225604","title":"What's Going On With Aldeyra Therapeutics Stock On Thursday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620225604","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620225604?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:01","pubTimestamp":1773925260,"startTime":"0","endTime":"0","summary":"Aldeyra stock plunges after FDA rejects its dry eye drug reproxalap, raising concerns over efficacy and future growth prospects.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/19/Doctor-Working-On-Virtual-Touch-Screen-P.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/19/Doctor-Working-On-Virtual-Touch-Screen-P.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/26/03/51352510/whats-going-on-with-aldeyra-therapeutics-stock-on-thursday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/26/03/51352510/whats-going-on-with-aldeyra-therapeutics-stock-on-thursday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4530","BK4121","CRL","LU0757428866.USD","BK4217","BK4588","LU1815336091.USD","LU0128526141.USD","LU0029874061.USD","SMA","IE00BFMHRM44.USD","BK4585","ALDX","LABU","BK4139","LU0390134368.USD"],"gpt_icon":0},{"id":"2620066268","title":"Levi & Korsinsky probes Aldeyra Therapeutics over potential securities fraud claims","url":"https://stock-news.laohu8.com/highlight/detail?id=2620066268","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620066268?lang=en_us&edition=fundamental","pubTime":"2026-03-19 00:36","pubTimestamp":1773851761,"startTime":"0","endTime":"0","summary":"Levi & Korsinsky said it has opened an investigation into Aldeyra Therapeutics over potential violations of U.S. federal securities laws. The firm is reviewing Aldeyra’s 2024 and 2025 statements about the development and regulatory prospects of reproxalap for dry eye disease. It cited an FDA Complete Response Letter dated March 17, 2026 stating that reproxalap had not demonstrated sufficient efficacy. The investigation is examining whether Aldeyra failed to disclose material information about efficacy risks.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL8DCpVx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2620237050","title":"Aldeyra Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2620237050","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620237050?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:13","pubTimestamp":1773832380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2026 07:13 ET (11:13 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX"],"gpt_icon":0},{"id":"2620232154","title":"HC Wainwright Downgrades Aldeyra Therapeutics to Neutral From Buy, Adjusts PT to $2 From $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2620232154","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620232154?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:43","pubTimestamp":1773830592,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics (ALDX) has an average rating of buy and mean price target of $8.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALDX"],"gpt_icon":0},{"id":"2620131234","title":"Aldeyra downgraded to Neutral from Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2620131234","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620131234?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:12","pubTimestamp":1773828748,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Matthew Caufield downgraded Aldeyra (ALDX) to Neutral from Buy with a price target of $2, down from $10, after the company ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aldeyra-downgraded-to-neutral-from-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aldeyra-downgraded-to-neutral-from-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALDX","BK4139"],"gpt_icon":0},{"id":"2620238304","title":"U.S. RESEARCH ROUNDUP-Factset, Lensar, Starbucks","url":"https://stock-news.laohu8.com/highlight/detail?id=2620238304","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620238304?lang=en_us&edition=fundamental","pubTime":"2026-03-18 15:36","pubTimestamp":1773819417,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Factset, Lensar, StarbucksMarch 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Wednesday, including Fa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nL8N4060HY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ECL","XYZG","ANRO","DUOL","BKKT","DOCU","CE","GLGG","STZ","XYZY","AJG","EQIX","APD","COHX","FDS","APGE","CTMX","BTGO","CADL","CF","XYZ","GEMI","GHM","ARCT","DC","CCL","CRC","HQY","ANDG","GEMG","CLH","ALDX","CLYM","GLXU","IE00BMG7P926.USD","DLR","BL","COHR","CALM","LU1992135472.HKD","ASO","LU1923621640.USD","GLXY","DOW","BTSG","EVMN","ETR","DTE","LU2360107671.USD","FICO"],"gpt_icon":0},{"id":"2620747514","title":"BUZZ-U.S. STOCKS ON THE MOVE  -Steel Dynamics, Aldeyra, Cencora","url":"https://stock-news.laohu8.com/highlight/detail?id=2620747514","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620747514?lang=en_us&edition=fundamental","pubTime":"2026-03-18 01:45","pubTimestamp":1773769530,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE  -Steel Dynamics, Aldeyra, CencoraWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nL6N4050NT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4516","LU0368265418.SGD","LU0127658192.USD","LU0149725797.USD","LU0466842654.USD","LU0612318385.USD","BK4213","LU1814569148.SGD","LU0081259029.USD","LU1861559042.SGD","LU1267930227.SGD","LU2023250843.SGD","BK4206","LU1839511570.USD","LU0531971165.HKD","BK4008","SGXZ51526630.SGD","SG9999015986.USD","BK4081","LU1066053197.SGD","IE00BVYPNP33.GBP","LU0912757837.SGD","LU0240878834.USD","LU1201861165.SGD","LU0240877869.USD","LU0266512127.USD","LU1064131342.USD","IE00BWXC8680.SGD","LU0306807586.USD","LU0648000940.SGD","OKLS","LU2237438978.USD","GB00BDT5M118.USD","BK4097","BK4141","LU0878866978.SGD","LU0130518102.USD","LU1035775433.USD","SG9999002224.SGD","BK4606","LU0006306889.USD","IE00BGHQDM52.EUR","LU0612318971.USD","LU1983260115.SGD","LU2106854487.HKD","LU0058720904.USD","LU0980610538.SGD","IE00B19Z9Z06.USD","LU1261432733.SGD","LU0985481810.HKD","LU0310800965.SGD","BK4581","LU0107464264.USD","LU0640476718.USD","LU1116320901.HKD","BK4135","SG9999014542.SGD","LU0265550946.USD","DRAY","LU0321505868.SGD","LU0130517989.USD","LU0256863811.USD","BK4142","LU1069344957.HKD","LU1883866441.USD","ABNG","BK4559","BK4554","BK4567","LU0742534661.SGD","LU1074936037.SGD","LU0757428866.USD","LU0203347892.USD","LU1150488218.USD","LU0788109394.HKD","LU1674673691.USD","SGXZ81514606.USD","LU1489326972.SGD","UBEW","SG9999015945.SGD","LU0070302665.USD","BK4566","LU1169589451.USD","BK4585","LU0353189763.USD","STLD","LU1815336091.USD","BK4094","BK4179","LU1316542783.SGD","LU0433182093.SGD","LU0654597011.USD","LU0106261372.USD","LU1823568750.SGD","UBRL","IE00B1XK9C88.USD","LU0345770993.USD","LU2087621335.USD","SG9999014559.SGD","LU1974910355.USD","SG9999015978.USD","LU2463526074.USD","LU0353189680.USD","LU1244550494.USD","BK4084","IE00BFXG1179.USD","LU0154245673.USD","IE00B894F039.SGD","LU0985489474.SGD","LU0070217475.USD","LU1280957306.USD","LU0300736062.USD","XOMZ","QCML","BK4551","SG9999004303.SGD","LU0792757196.USD","LU0300736492.USD","LU0868494617.USD","LU0889566641.SGD","SG9999018865.SGD","SG9999002521.SGD","IE00BZ9MQY76.HKD","LU1582987324.SGD","LU0942090050.USD","LU0251131958.USD","SG9999001440.SGD","IE0034235303.USD","SG9999015952.SGD","LU0208291251.USD","BK4526","IE00BVYPNQ40.USD","LU2133065610.SGD","LU0787776722.HKD","IE00B3QW5Z07.USD","BK4500","BK4590","LU2592432038.USD","LU0642271901.SGD","LU0203345920.USD","IE00B1BXHZ80.USD","IE00BZ199S13.USD","LU0098860793.USD","LU2347655156.SGD","IE00B3T34201.USD","LU0683600562.USD","BK4139","NBIG","BK4515","LU1267930813.SGD","BK4077","OKLL","LU0477156953.USD","BK4216","LU0053671581.USD","LU2247934214.USD","IE00B64PRP62.GBP","AALG","LU2129689431.USD","LU0329931090.USD","LU1496350502.SGD","LU1585245621.USD","LU1430594728.SGD","BK4150","LU2237957902.USD","LU0265550359.USD","BK4512","BK4529","NEBX","ALDX","IE00B2Q91V27.USD","LU0278409577.USD","IE00B3CCJ963.GBP","LU0256331488.USD","SG9999014898.SGD","LU0054578231.USD","LU0225771236.USD","XOMO","LU1917777945.USD","LU0130102774.USD","IE00BFMHRM44.USD","LU0795875169.SGD","IE0002270589.USD","IE00B19Z3B42.SGD","LU1582987597.SGD","LU0306806265.USD","LU1582986433.USD","LU0082616367.USD","LU1201861249.SGD","BK4604","SG9999018857.SGD","LU2602419157.SGD","BK4022","BK4598","SG9999017495.SGD","LU1244550221.USD","LU0266512473.USD","LU0061475181.USD","LU0068578508.USD","LU0477156797.USD","LU0122376428.USD","LU1066051498.USD","LU2360107325.USD","BK4609","LU0079474960.USD","ABNY","BK4539","LU0345780950.USD","LU0823431647.USD","LU2087625088.SGD","LU2237957811.SGD","LU2381873111.SGD","BK4175","LU2505996681.GBP","BK4505","LU0648001328.SGD","LU0868494708.USD","BK4201","LU0950373646.USD","BK4171","LU1119994496.HKD","LU1861219969.SGD","LU2498475776.HKD","BK4602","LU0289739699.SGD","SG9999015358.SGD","BK4519","SG9999001424.SGD","COR","LU1150488135.SGD","LU0048573561.USD","BK4597","LU0417517546.SGD","LU0345770308.USD","LU2505996509.AUD","DKNX","BK4144","SGXZ99366536.SGD","BK4579","LU2430703095.HKD","LU1496350171.SGD","LU1084165304.USD","NBIL","LU2097829019.USD","LU2264538146.SGD","BK4550","LU2462611646.USD","LU0211331839.USD","LU1162221912.USD","IE00B7SZLL34.SGD","LU0795875086.SGD","SG9999014575.USD","BK4006","BK4230","LU0329931173.USD","QCMU","BK4532","SG9999014880.SGD","LU1244550577.SGD","BK4082","BK4527","SG9999014914.USD","LU1430597077.USD","LU1674673428.USD","LU0234572021.USD","LU1732800096.USD","LU1778281490.HKD","SG9999015341.SGD","LU1878469433.USD","LU1861214812.USD","IE00BGHQF524.EUR","BK4570","LU2430703251.USD","IE00B19Z9P08.USD","BK4592","BK4575","LU2430703178.SGD","IE00BKDWB100.SGD","LU2129689605.HKD","LU0128525689.USD","LU0052756011.USD","SGXZ31699556.SGD","SG9999014906.USD","LU2023250504.SGD","IE000M9KFDE8.USD","LU1929549753.HKD","IE0034235188.USD","LU0345781412.USD","LU0251142724.SGD","LU0320765646.SGD","LU1153585028.USD","LU1718418525.SGD","DKUP","BK4588","BK4547","IE00BSNM7G36.USD","BK4573","SGXZ23171101.USD","BK4534","IE00BGHQF748.EUR","BK4535","LU0170899867.USD","LU1861558580.USD","LU1988902786.USD","LU1582986359.USD","BK4161","LU0225284248.USD","LU2324357040.USD","LU0823431563.USD","NBIZ","LU1169590202.USD","LU1894683348.USD","QCMD","LU0321505439.SGD","LU1894683264.USD","LU2129689514.USD","IE00B19Z3581.USD","XOMX","BK4503","LU0456854461.SGD","SG9999002232.USD","SG9999014567.USD","BK4536","LU0320765489.SGD","LU1732799900.SGD","BK4612","LU0011850046.USD","LU1046421795.USD","BK4605","LU0154245756.USD","LU0130103400.USD","BK4224","BK4138","BK4561","BK4565","LU0719512351.SGD","LU1116320737.USD","LU0630314457.HKD"],"gpt_icon":0},{"id":"2620478584","title":"Aldeyra Therapeutics Shares Hit Record Low After US FDA Declines to Approve Eye Disorder Drug, Last Down 70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620478584","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620478584?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:49","pubTimestamp":1773755344,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nFWN40507T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALDX","BK4139"],"gpt_icon":0},{"id":"2620569420","title":"Aldeyra Therapeutics Shares Fall as Drug Rejected by Regulator on Efficacy Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2620569420","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620569420?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:19","pubTimestamp":1773753540,"startTime":"0","endTime":"0","summary":"Shares of Aldeyra Therapeutics fell sharply in premarket trading Tuesday said the U.S. health regulator rejected its dry-eye drug, saying that the company failed to show the treatment works.The biotechnology company on Tuesday said it received a complete response letter from the U.S. Food and Drug Administration for its new drug application of reproxalap, which is an investigational drug candidate, to treat dry eye disease.The FDA said Aldeyra failed to provide substantial, well-controlled evidence that reproxalap works, citing inconsistent trial results and a lack of demonstrated efficacy in treating dry eye disease. The agency also said the data doesn't support the drug's effectiveness, though it raised no safety or manufacturing concerns.Aldeyra noted that the FDA didn't recommend conducting additional trials or request submission of additional confirmatory evidence.In the meantime, Aldeyra won't pursue any new clinical trials, but said it plans to meet with the FDA to understand th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Aldeyra Therapeutics Shares Fall as Drug Rejected by Regulator on Efficacy Concerns","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2620695420","title":"FDA issues Aldeyra CRL saying reproxalap NDA failed to demonstrate efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2620695420","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620695420?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:11","pubTimestamp":1773753069,"startTime":"0","endTime":"0","summary":"Aldeyra (ALDX) announced receipt of a complete response letter, or CRL, from the FDA for the new drug application, or NDA, of reproxalap, an invest...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-issues-aldeyra-crl-saying-reproxalap-nda-failed-to-demonstrate-efficacy-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-issues-aldeyra-crl-saying-reproxalap-nda-failed-to-demonstrate-efficacy-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU0390134368.USD","LU0757428866.USD","CRL","LU0029874061.USD","BK4530","IE00BFMHRM44.USD","ALDX","LU0128526141.USD","BK4121","BK4139","BK4588","LABU","LU1815336091.USD"],"gpt_icon":0},{"id":"2620203004","title":"How Did the FDA Shatter Investor Confidence In Aldeyra Therapeutics Stock (ALDX) Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620203004","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620203004?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:10","pubTimestamp":1773753025,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics stock fell hard on Tuesday after it received a CRL from the FDA.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/how-the-fda-shattered-investor-confidence-in-aldeyra-therapeutics-stock-aldx-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/how-the-fda-shattered-investor-confidence-in-aldeyra-therapeutics-stock-aldx-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","ALDX","LABU","BK4139","BK4588"],"gpt_icon":0},{"id":"2620427261","title":"Aldeyra Therapeutics Shares Down 73% Premarket After US FDA Declines to Approve Eye Disorder Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2620427261","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620427261?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:06","pubTimestamp":1773752800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nL4N40515U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2620642402","title":"FDA issues complete response letter for Aldeyra’s reproxalap dry eye NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2620642402","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620642402?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:30","pubTimestamp":1773750620,"startTime":"0","endTime":"0","summary":"Aldeyra said the FDA issued a Complete Response Letter for the reproxalap New Drug Application for dry eye disease, citing a lack of substantial evidence from adequate and well-controlled studies to support efficacy. The FDA also said inconsistency of study results raised concerns about the reliability and meaningfulness of positive findings, and that the totality of evidence from completed clinical trials did not support effectiveness. Aldeyra reported cash, cash equivalents, and marketable securities of USD 70 million as of Dec. 31, 2025, and said it expects this to support operations into 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL12ybVW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2620942408","title":"Aldeyra Therapeutics Inc - No Safety or Manufacturing Concerns Identified in Reproxalap Nda Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2620942408","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620942408?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:30","pubTimestamp":1773750600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nTUA4L7FQJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALDX","BK4139"],"gpt_icon":0},{"id":"2620703424","title":"Aldeyra Therapeutics Inc - FDA States Reproxalap Nda Failed to Demonstrate Efficacy for Dry Eye Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2620703424","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620703424?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:30","pubTimestamp":1773750600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nTUA4L7FQJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALDX","BK4139"],"gpt_icon":0},{"id":"2620424085","title":"Aldeyra Therapeutics Receives Complete Response Letter From the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2620424085","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620424085?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:30","pubTimestamp":1773750600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nTUA4L7FQJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2620424066","title":"Aldeyra Therapeutics Inc - to Request Type a Meeting With FDA Within 30 Days per Pdufa Goals","url":"https://stock-news.laohu8.com/highlight/detail?id=2620424066","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620424066?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:30","pubTimestamp":1773750600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nTUA4L7FQJ:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALDX","BK4139"],"gpt_icon":0},{"id":"2620240824","title":"Aldeyra Therapeutics Inc - FDA Recommends Exploring Trial Failures; No Additional Trials Requested for Reproxalap","url":"https://stock-news.laohu8.com/highlight/detail?id=2620240824","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620240824?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:30","pubTimestamp":1773750600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nTUA4L7FQJ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALDX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aldeyra.com;ir.aldeyra.com","stockEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":-0.6776},{"period":"3month","weight":-0.6667},{"period":"6month","weight":-0.6509},{"period":"1year","weight":-0.7173},{"period":"ytd","weight":-0.6583}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0852},{"period":"3month","weight":-0.0814},{"period":"6month","weight":-0.0419},{"period":"1year","weight":0.1182},{"period":"ytd","weight":-0.0701}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.071524},{"month":2,"riseRate":0.583333,"avgChangeRate":-0.000501},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.047431},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.007872},{"month":5,"riseRate":0.363636,"avgChangeRate":0.012368},{"month":6,"riseRate":0.333333,"avgChangeRate":0.032526},{"month":7,"riseRate":0.583333,"avgChangeRate":0.052566},{"month":8,"riseRate":0.5,"avgChangeRate":0.050447},{"month":9,"riseRate":0.5,"avgChangeRate":0.169785},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.091942},{"month":11,"riseRate":0.666667,"avgChangeRate":0.079554},{"month":12,"riseRate":0.416667,"avgChangeRate":-0.031913}],"exchange":"NASDAQ","name":"Aldeyra Therapeutics","nameEN":"Aldeyra Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aldeyra Therapeutics(ALDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aldeyra Therapeutics(ALDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aldeyra Therapeutics,ALDX,Aldeyra Therapeutics股票,Aldeyra Therapeutics股票老虎,Aldeyra Therapeutics股票老虎国际,Aldeyra Therapeutics行情,Aldeyra Therapeutics股票行情,Aldeyra Therapeutics股价,Aldeyra Therapeutics股市,Aldeyra Therapeutics股票价格,Aldeyra Therapeutics股票交易,Aldeyra Therapeutics股票购买,Aldeyra Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aldeyra Therapeutics(ALDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aldeyra Therapeutics(ALDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}